Clinical Research Directory

Inclusion Criteria: * \>= 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors (with or without adjuvant CDK 4/6 inhibitors such as abemaciclib), or androgen deprivation are allowed. * Scheduled for a routine cancer-related follow-up care visit within the next 30 days with a provider who received training to use AH-HA. * Able and willing to complete a follow-up assessment in one year. * Survivors must have no evidence of disease at the time of last medical visit for all cancers, except non-melanoma skin disease. * Age \>= 18 years. * Able to understand and willing to provide verbal informed consent. Exclusion Criteria: * Survivors will be excluded if they have a history of cancer recurrence for any cancer other than non-melanoma skin disease. * Prostate patients on active surveillance will be excluded. * Survivor does not speak English or Spanish. * Survivors who are currently on another interventional protocol in which cardiovascular risk factors (e.g., blood pressure, smoking, diet, physical activity) are being addressed, as per patient self-report or research staff members' knowledge at the time of consent.